Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cintirorgon - Celgene/Lycera

X
Drug Profile

Cintirorgon - Celgene/Lycera

Alternative Names: LYC 55716

Latest Information Update: 28 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lycera
  • Class Antineoplastics; Benzoxazines; Fluorinated hydrocarbons; Propionic acids; Small molecules; Sulfones
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 agonists; Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 28 Oct 2022 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 27 Oct 2020 Phase II development is ongoing in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO) (Lycera's pipeline, October 2020)
  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top